BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.

The higher revenues in the third quarter were largely attributed to the earlier approvals received for its variant-adapted COVID-19 vaccines compared to last year.

The COVID-19 vaccine maker reported a third-quarter net profit of 198.1 million euros, up from 160.6 million euros a year ago. BioNTech reported EPS of 81 cents, up from ...